Toll Free: 1-888-928-9744

miRagen Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

miRagen Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'miRagen Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the miRagen Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of miRagen Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of miRagen Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of miRagen Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the miRagen Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate miRagen Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of miRagen Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the miRagen Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of miRagen Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of miRagen Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of miRagen Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
miRagen Therapeutics, Inc. Snapshot 5
miRagen Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
miRagen Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
miRagen Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
miRagen Therapeutics, Inc. - Pipeline Products Glance 11
miRagen Therapeutics, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
miRagen Therapeutics, Inc. - Drug Profiles 13
MGN-1374 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
MGN-4220 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
MGN-4893 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
MGN-5804 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MGN-6114 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
MGN-8107 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MGN-9103 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Oligonucleotide for Cardiometabolic Diseases 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RNAi Oligonucleotide to Inhibit miR-145 for PAH 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Antisense Oligonucleotide for Cardivascular Disease 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
miRagen Therapeutics, Inc. - Pipeline Analysis 23
miRagen Therapeutics, Inc. - Pipeline Products by Target 23
miRagen Therapeutics, Inc. - Pipeline Products by Molecule Type 24
miRagen Therapeutics, Inc. - Pipeline Products by Mechanism of Action 25
miRagen Therapeutics, Inc. - Recent Pipeline Updates 26
miRagen Therapeutics, Inc. - Dormant Projects 28
miRagen Therapeutics, Inc. - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31
List of Tables
miRagen Therapeutics, Inc., Key Information 5
miRagen Therapeutics, Inc., Key Facts 5
miRagen Therapeutics, Inc. - Pipeline by Indication, 2014 8
miRagen Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
miRagen Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
miRagen Therapeutics, Inc. - Preclinical, 2014 11
miRagen Therapeutics, Inc. - Discovery, 2014 12
miRagen Therapeutics, Inc. - Pipeline by Target, 2014 23
miRagen Therapeutics, Inc. - Pipeline by Molecule Type, 2014 24
miRagen Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 25
miRagen Therapeutics, Inc. - Recent Pipeline Updates, 2014 26
miRagen Therapeutics, Inc. - Dormant Developmental Projects,2014 28 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify